The experimental antibody drug given to President Donald Trump has been called one of the most promising approaches to preventing serious illness from a COVID-19 infection.
Its maker, Regeneron Pharmaceuticals Inc., said the company agreed to supply a single dose, given through an IV, for Trump at the request of his physician under “compassionate use” provisions, when an experimental medicine is provided on a case-by-case emergency basis, while studies of it continue.
The new drug is in late-stage testing and its safety and effectiveness are not yet known. No treatment has yet proved able to prevent serious illness after a coronavirus infection.
Trump was given the experimental drug at the White House on Friday before he was taken to Walter Reed National Military Medical Center, where he’ll be monitored, officials said. So far, Trump has had only mild symptoms, including fatigue.
Regeneron’s drug contains two antibodies to enhance the chances that it will work. The company previously developed a successful Ebola treatment from an antibody combo.
The drug is given as a one-time treatment through an IV. In multiple studies, Regeneron is testing it both for preventing infection and in people already infected, like Trump, to try to prevent serious illness or death.
Earlier this week, Regeneron said partial results from about 275 COVID-19 patients who were not sick enough to need hospitalization suggested it might be cutting how long symptoms last and helping reduce the amount of virus patients harbor.
Subscribe to our YouTube channel: [ Ссылка ]
QUICKTAKE ON SOCIAL:
Follow QuickTake on Twitter: twitter.com/quicktake
Like QuickTake on Facebook: facebook.com/quicktake
Follow QuickTake on Instagram: instagram.com/quicktake
Subscribe to our newsletter: [ Ссылка ]
Email us at quicktakenews@gmail.com
QuickTake by Bloomberg is a global news network delivering up-to-the-minute analysis on the biggest news, trends and ideas for a new generation of leaders.
